Artificial intelligence is still struggling to crack the most complex problem in pharma R&D: reliably designing new molecules that become breakthrough medicines. But drugmakers say AI is already paying off in the “unsexy” middle of development. This is where time and money are often lost to paperwork, vendor hand-offs, and slow trial start-up. At the JPMorgan Healthcare Conference in January…
Tag: JP Morgan Healthcare Conference
-
European Drug Pricing Dispute Escalates Over US Deals
Global pharmaceutical companies are entering 2026 facing a high-stakes European drug pricing dispute as they seek to offset recent price concessions in the United States. Following intense pressure from President Donald Trump, who secured major drug price cuts for American patients in late 2025, companies are now turning to Europe to recoup revenue losses. Manufacturers such as Pfizer, Eli Lilly, and AstraZeneca have…